Keyphrases
Middle East Respiratory Syndrome Coronavirus (MERS-CoV)
100%
Receptor-binding Domain
100%
Neutralizing Monoclonal Antibody
100%
Coronavirus Spike Protein
100%
Coronavirus Infections
21%
Human Cells
14%
Humanized
14%
Dipeptidyl peptidase-4 (DPP-4)
14%
Coronavirus Entry
14%
Therapeutic Strategies
7%
Fatality
7%
Subunit Vaccine
7%
Cell Surface Receptor
7%
Antigenicity
7%
Therapeutic Agents
7%
Human Population
7%
Rational Design
7%
Binding Surface
7%
Severe Respiratory Failure
7%
Prophylactic Strategy
7%
Biochemical Assay
7%
Humanized Antibody
7%
Prophylactic Treatment
7%
Over 40
7%
Healthcare Workers
7%
Neutralizing Epitope
7%
Coronavirus Receptors
7%
Therapeutic Antibody
7%
Coronavirus Vaccine
7%
Alanine Scanning
7%
Patient's Family Member
7%
Immunology and Microbiology
Monoclonal Antibody
100%
Middle East Respiratory Syndrome Coronavirus
100%
Receptor Binding
100%
Spike
100%
Conformation
100%
Infection
35%
Human Cell
14%
Dipeptidyl Peptidase IV
14%
Subunit Vaccine
7%
Antigenicity
7%
Epitope
7%
Humanized Antibody
7%
Therapeutic Antibodies
7%
Alanine
7%
Medicine and Dentistry
Monoclonal Antibody
100%
Middle East Respiratory Syndrome Coronavirus
100%
Receptor Binding
100%
Middle East Respiratory Syndrome
27%
Infection
18%
Dipeptidyl Peptidase IV
18%
Receptor
9%
Fatality
9%
Therapeutic Agent
9%
Respiratory Disease
9%
Epitope
9%
Alanine
9%
Subunit Vaccine
9%
Antigenicity
9%
Health Care Personnel
9%
Pharmacology, Toxicology and Pharmaceutical Science
Receptor
100%
Monoclonal Antibody
100%
Middle East Respiratory Syndrome Coronavirus
100%
Middle East Respiratory Syndrome
27%
Infection
18%
Dipeptidyl Peptidase IV
18%
Fatality
9%
Subunit Vaccine
9%
Respiratory Tract Disease
9%
Epitope
9%
Alanine
9%